Delayed GlaxoWellcome-SmithKline Merger Slows Plans to Expand Bioinformatics Team | GenomeWeb

Delays in completing the merger of GlaxoWellcome and SmithKline Beecham have made hiring more bioinformaticists extremely difficult because people do not want to join a company where the future path is unclear, executives said.

That is one reason the two London-based companies can’t wait until the deal closes – which they expect to happen by year’s end, said Allen Roses, vice president and worldwide director of genetics at GlaxoWellcome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.